Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David T Dunn

Showing results (1-10 of 77) with videos related to

Pageof 8
Sort By:
Statistical Communications in Infectious Diseases|August 31, 2019
The Connection between the Averted Infections Ratio and the Rate Ratio in Active-control Trials of Pre-exposure Prophylaxis AgentsDavid T Dunn, David V Glidden
BMC Medical Research Methodology|June 28, 2018
Estimation of delay to diagnosis and incidence in HIV using indirect evidence of infection datesOliver T Stirrup, David T Dunn
Current Opinion in HIV and AIDS|November 7, 2015
Statistical issues in trials of preexposure prophylaxisDavid T Dunn, David V Glidden
Current Opinion in HIV and AIDS|June 8, 2011
Genotypic resistance testing in routine clinical careDavid T Dunn, Kate Coughlin, Patricia A Cane
Trials|September 19, 2018
Superiority and non-inferiority: two sides of the same coin?David T Dunn, Andrew J Copas, Peter Brocklehurst
BMC Medical Research Methodology|March 16, 2012
Effect of misclassification of antiretroviral treatment status on the prevalence of transmitted HIV-1 drug resistanceHannah Castro, Deenan Pillay, Caroline Sabin, et al.
The Lancet. HIV|October 31, 2020
A Bayesian averted infection framework for PrEP trials with low numbers of HIV infections: application to the results of the DISCOVER trialDavid V Glidden, Oliver T Stirrup, David T Dunn
Clinical Trials (London, England)|October 23, 2025
Sample size estimation for the averted events ratioDavid T Dunn, Oliver T Stirrup, David V Glidden
Statistics in Medicine|April 2, 2004
Interval-censored survival time data: confidence intervals for the non-parametric survivor functionRuth L Goodall, David T Dunn, Abdel G Babiker
Statistical Communications in Infectious Diseases|July 26, 2022
Confidence limits for the averted infections ratio estimated via the counterfactual placebo incidence rateDavid T Dunn, Oliver T Stirrup, David V Glidden
Pageof 8

Showing results (1-10 of 77) with videos related to

Sort By:
Pageof 8
Statistical Communications in Infectious Diseases|August 31, 2019
The Connection between the Averted Infections Ratio and the Rate Ratio in Active-control Trials of Pre-exposure Prophylaxis AgentsDavid T Dunn, David V Glidden
BMC Medical Research Methodology|June 28, 2018
Estimation of delay to diagnosis and incidence in HIV using indirect evidence of infection datesOliver T Stirrup, David T Dunn
Current Opinion in HIV and AIDS|November 7, 2015
Statistical issues in trials of preexposure prophylaxisDavid T Dunn, David V Glidden
Current Opinion in HIV and AIDS|June 8, 2011
Genotypic resistance testing in routine clinical careDavid T Dunn, Kate Coughlin, Patricia A Cane
Trials|September 19, 2018
Superiority and non-inferiority: two sides of the same coin?David T Dunn, Andrew J Copas, Peter Brocklehurst
BMC Medical Research Methodology|March 16, 2012
Effect of misclassification of antiretroviral treatment status on the prevalence of transmitted HIV-1 drug resistanceHannah Castro, Deenan Pillay, Caroline Sabin, et al.
The Lancet. HIV|October 31, 2020
A Bayesian averted infection framework for PrEP trials with low numbers of HIV infections: application to the results of the DISCOVER trialDavid V Glidden, Oliver T Stirrup, David T Dunn
Clinical Trials (London, England)|October 23, 2025
Sample size estimation for the averted events ratioDavid T Dunn, Oliver T Stirrup, David V Glidden
Statistics in Medicine|April 2, 2004
Interval-censored survival time data: confidence intervals for the non-parametric survivor functionRuth L Goodall, David T Dunn, Abdel G Babiker
Statistical Communications in Infectious Diseases|July 26, 2022
Confidence limits for the averted infections ratio estimated via the counterfactual placebo incidence rateDavid T Dunn, Oliver T Stirrup, David V Glidden
Pageof 8